With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.
5 mmol of 1,4,7-triazacyclononane (645 mg) and benzaldehyde (508 muL, 5 mmol) were stirred at room temperature in distilled ethanol (80 mL) containing molecular sieve for 4 h. The solution was filtered and evaporated under reduced pressure to yield the aminal product as a white solid (980 mg, 4.5 mmol, 90%). NMR (CDCl3) 1H (300 MHz) 2.89-2.93 (m, 4H,CH2tacn) 2.99-3.03 (m, 2H,CH2tacn) 3.07-3.17 (m, 4H,CH2tacn) 3.32-3.39 (m, 2H,CH2tacn) 5.66 (s, 1H, Haminal) 7.18 (t, 1H, HPhe) 7.29 (t, 2H, HPhe) 7.50 (2H, d, HPhe); 13C (75 MHz) 49.3 49.6 58.8 (CH2tacn) 88.3 (Caminal) 126.6, 126.7 128.2 (CHPhe) 145.8 (CPhe).
4730-54-5, 4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Article; Roger, Melissa; Patinec, Veronique; Tripier, Raphael; Triki, Smail; Poul, Nicolas Le; Mest, Yves Le; Inorganica Chimica Acta; vol. 417; (2014); p. 201 – 207;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI